KARI, E. J. M., KUUSISTO, M. E. L., BÖHM, J., HAAPASAARI, K.-M., TEPPO, H.-R., KARIHTALA, P., HAKALAHTI, A., TURPEENNIEMI-HUJANEN, T., & KUITTINEN, O. (2019). Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma. Anticancer Research, 39(9), 4925–4931. https://doi.org/10.21873/anticanres.13680
Peroxiredoxin 6 serum levels and risk of neutropenic infections in diffuse large B-cell lymphoma
|Author:||Kari, Esa Jaakko Mikael1; Kuusisto, Milla Elvi Linnea1; Böhm, Jan2;|
1Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
2Department of Pathology, Central Finland Central Hospital, Jyväskylä, Finland
3Cancer Research and Translational Medicine Research Unit, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland
4Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
|Online Access:||PDF Full Text (PDF, 0.4 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020040110050
International Institute of Anticancer Research,
|Publish Date:|| 2019-07-15
Background/Aim: Diffuse large B‐cell lymphoma (DLBCL) is an aggressive malignancy where antioxidant enzyme peroxiredoxin 6 (Prx6) has previously been associated with adverse outcomes. Its systemic effects in DLBCL are unknown.
Materials and methods: This study included 53 patients with DLBCL, five patients with primary central nervous system lymphoma (PCNSL) and 20 healthy controls. The expression of Prx6 was evaluated immunohistochemically in DLBCL tissue samples and compared to its expression in blood serum.
Results: Prx6 expression was the highest in healthy controls, followed by DLBCL patients and PCNSL patients. Febrile neutropenic infection after the first treatment course was associated with low pre-treatment Prx6 serum levels (<14 ng/ml) (p=0.025, OR=8.615, 95% confidence interval=1.032‐71.933). Serum levels of Prx6 recovered after treatment (p=0.006).
Conclusion: Patients with low Prx6 levels might be more prone to treatment‐related adverse effects through elevated levels of oxidative stress.
|Pages:||4925 - 4931|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This study was conducted as a part of a thesis project with no specific grants. Teppo would like to acknowledge the financial support from the Finnish Medical Foundation, the Finnish medical society Duodecim, the Thelma Mäkikyrö foundation and the Finnish Society for Oncology. Turpeenniemi-Hujanen would like to acknowledge the financial support from the Väisänen Foundation.
Copyright © 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. Published in this repository with the kind permission of the publisher.